The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or relapsed/refractory multiple myeloma (MM). Daratumumab was previously approved as an intravenous treatment for patients with MM. The combination of daratumumab and hyaluronidase-fihj is co-formulated with recombinant human hyaluronidase PH20 to allow subcutaneous injection. The treatment is approved...Continue Reading